Deepak Bhatt, MD: Sotagliflozin and Phase 3 Data from AHA 2020


Deepak Bhatt, MD, MPH, offers his thoughts on the results of SCORED and SOLOIST as well as diving deeper into the implications of the data for sotagliflozin and SGLT2 inhibitors moving forward.

Among the thousands of studies presented at the American Heart Association’s Scientific Sessions 2020 were a pair of late-breaking studies presented by Deepak Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital. Titled SCORED and SOLOIST, the pair of phase 3 trials examined use of sotagliflozin in patients with type 2 diabetes and worsening heart failure or chronic kidney disease.

While diabetes medications have stolen headlines at major cardiovascular meetings in the past few years, sotagliflozin sets itself apart from dapagliflozin and empagliflozin as the only dual SGLT2/1 inhibitor currently in development for treatment of type 1 and type 2 diabetes. As part of Practical Cardiology’s coverage of the annual conference, we reached out to Bhatt for further insight into the results of SOLOIST and SCORED—that conversation Is the subject of this special edition AHA 2020 House Call.

Related Videos
A panel of 3 experts on ocular diseases and conditions
4 KOLs are featured in this series
Sorana Segal-Maurer, MD, an expert on HIV
Sorana Segal-Maurer, MD, an expert on HIV
4 KOLs are featured in this series
M. Safwan Badr, MD: Novel Treatments for Central Sleep Apnea in Last 10 Years
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
© 2024 MJH Life Sciences

All rights reserved.